1T3 Panoramica delle azioni Syndax Pharmaceuticals, Inc. è una società biofarmaceutica in fase clinica che sviluppa terapie per il trattamento del cancro. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Syndax Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Syndax Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$14.80 Massimo di 52 settimane US$22.20 Minimo di 52 settimane US$11.90 Beta 0.90 Variazione di 1 mese 15.63% Variazione a 3 mesi -24.10% Variazione di 1 anno -26.73% Variazione a 3 anni 8.03% Variazione a 5 anni 73.10% Variazione dall'IPO 2.30%
Notizie e aggiornamenti recenti
Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan 16
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial Dec 10
Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting Dec 08
Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation Nov 16
New minor risk - Share price stability Nov 13
Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib Nov 13 Vedi altri aggiornamenti
Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan 16
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial Dec 10
Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting Dec 08
Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation Nov 16
New minor risk - Share price stability Nov 13
Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib Nov 13
Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting Nov 05
Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 29
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
New minor risk - Share price stability Aug 05
Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia Jul 30
Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25 Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index
SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress Jun 17
Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC Jun 08
Syndax Pharmaceuticals, Inc. Announces Board Changes May 16
Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Apr 09
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024 Apr 03
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Mar 28
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia Mar 27
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 19
New minor risk - Profitability Feb 29
Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 21
Now 24% undervalued Dec 20 Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.
Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting Dec 13
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting Nov 03
Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program Oct 25
New minor risk - Share price stability Oct 05
Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis Oct 05
Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 26
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25
Syndax Pharmaceuticals, Inc. Announces Executive Changes May 10 Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer Dec 03
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021) Nov 05
Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias Nov 04
Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
First half 2022 earnings released Aug 09
Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 03
Insufficient new directors Aug 02
Investor sentiment improved over the past week Jun 25
Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer Jun 14
Investor sentiment improved over the past week Jun 01
First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.54 loss in 1Q 2021) May 11
Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
Investor sentiment improved over the past week Apr 07
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 31
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 30
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 03
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 03
Syndax Pharmaceuticals, Inc. Announces Executive Changes Feb 25
Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24 Syndax Pharmaceuticals, Inc. Announces Executive Changes
Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 Dec 15
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease Dec 12
Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.46 loss in 3Q 2020) Nov 16
Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million. Sep 29
First half 2021 earnings released: US$0.98 loss per share (vs US$0.97 loss in 1H 2020) Aug 11
First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.56 loss in 1Q 2020) May 13
Independent Chairman recently bought €164k worth of stock Apr 24
Full year 2020 earnings released: US$1.87 loss per share (vs US$1.84 loss in FY 2019) Mar 10
Revenue beats expectations Mar 10
Syndax Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 08, 2021 Mar 02
Syndax Pharmaceuticals, Inc. Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD Dec 09
New 90-day high: €19.50 Dec 05
Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting Nov 06
New 90-day high: €16.00 Nov 05
Third quarter 2020 earnings released: US$0.46 loss per share Nov 05
Revenue misses expectations Nov 05
Syndax Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 02, 2020 Oct 28
New 90-day high: €15.30 Oct 19
New 90-day high: €14.50 Sep 17
First half earnings released Aug 07 Syndax Pharmaceuticals, Inc. announced that it has received funding from Frazier Healthcare Partners Jun 30
Rendimenti per gli azionisti 1T3 DE Biotechs DE Mercato 7D 10.4% 2.3% 0.5% 1Y -26.7% -2.6% 15.3%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 1T3 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -2.6 % nell'ultimo anno.
Rendimento vs Mercato: 1T3 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 15.3 % nell'ultimo anno.
Volatilità dei prezzi Is 1T3's price volatile compared to industry and market? 1T3 volatility 1T3 Average Weekly Movement 10.7% Biotechs Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di 1T3 è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 11% ) di 1T3 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2005 184 Michael Metzger www.syndax.com
Syndax Pharmaceuticals, Inc. è una società biofarmaceutica in fase clinica che sviluppa terapie per il trattamento del cancro. I suoi principali prodotti candidati sono revumenib, un potente e selettivo inibitore di piccole molecole dell'interazione di legame menina-MLL per il trattamento delle leucemie acute riarrangiate KMT2A e dei tumori solidi, e SNDX-6352 o axatilimab, un anticorpo monoclonale che blocca il fattore stimolante le colonie 1, o recettore CSF-1, per il trattamento di pazienti affetti da malattia cronica del trapianto contro l'ospite (cGVHD) e fibrosi polmonare idiopatica (IPF). L'azienda sta inoltre sviluppando Entinostat.
Mostra di più Syndax Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Syndax Pharmaceuticals con la sua capitalizzazione di mercato? 1T3 statistiche fondamentali Capitalizzazione di mercato €1.20b Guadagni(TTM ) -€285.98m Ricavi(TTM ) €15.40m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 1T3 Conto economico (TTM ) Ricavi US$16.00m Costo del fatturato US$64.19m Profitto lordo -US$48.19m Altre spese US$248.87m Guadagni -US$297.06m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -3.48 Margine lordo -301.21% Margine di profitto netto -1,856.64% Rapporto debito/patrimonio netto 0%
Come si è comportato 1T3 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/06 10:58 Prezzo dell'azione a fine giornata 2025/02/06 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Syndax Pharmaceuticals, Inc. è coperta da 23 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Peter Lawson Barclays Jason Zemansky BofA Global Research Madhu Kumar B. Riley Securities, Inc.
Mostra 20 altri analisti 
